HLS.TO
HLS Therapeutics Inc.
TorontoCADEQUITY
Healthcare
DELAYED
Last price
3.75
▼ 0.19 (4.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.92
Prev close
3.94
Day high
3.92
Day low
3.56
Volume
126.83K
Market cap
$116.01M
P/E (TTM)
—
52W range
0.00 – 5.77
Day trading desk
Gap from prior close
-0.51%
Prior close 3.94
VWAP
3.72
+0.73% from price
Relative volume
4.59×
Unusually busy
Session range
10.11%
3.56 – 3.92
Position in range
53%
Mid range
ATR (14D)
0.20
5.32% of price
Prior day high
3.95
PDH
Prior day low
3.71
PDL
Bid / ask spread
—
Quote not published
Session volume
253.35K
Avg 55.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.85%
-2.5%
1M
-10.93%
-14.7%
3M
-19.18%
-22.3%
6M
-16.67%
-27.7%
YTD
-22.20%
-34.5%
1Y
-26.76%
-46.8%
3Y
-25.00%
-99.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HLS.TO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
166.43K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | Millian (Craig Stuart) Director of Issuer |
BUY | 2.00K | $5.58K | Direct |
| Jun 17, 26 | Millian (Craig Stuart) Director of Issuer |
BUY | 2.00K | $6.32K | Direct |
| Jun 16, 26 | Hanna, John Gordon Director of Issuer |
BUY | 4.00K | $12.29K | Direct |
| Sep 30, 25 | HLS Therapeutics Inc. Issuer |
BUY | 500 | $2.05K | Direct |
| Sep 30, 25 | HLS Therapeutics Inc. Issuer |
BUY | 1.00K | $4.13K | Direct |
| Sep 30, 25 | HLS Therapeutics Inc. Issuer |
— | 1.50K | — | Direct |
| Sep 29, 25 | HLS Therapeutics Inc. Issuer |
BUY | 100 | $395 | Direct |
| Sep 29, 25 | HLS Therapeutics Inc. Issuer |
— | 100 | — | Direct |
| Sep 26, 25 | HLS Therapeutics Inc. Issuer |
BUY | 3.20K | $12.24K | Direct |
| Sep 26, 25 | HLS Therapeutics Inc. Issuer |
BUY | 2.10K | $8.01K | Direct |
| Sep 26, 25 | HLS Therapeutics Inc. Issuer |
— | 5.30K | — | Direct |
| Sep 25, 25 | HLS Therapeutics Inc. Issuer |
BUY | 3.40K | $13.32K | Direct |
| Sep 25, 25 | HLS Therapeutics Inc. Issuer |
BUY | 1.20K | $4.66K | Direct |
| Sep 25, 25 | HLS Therapeutics Inc. Issuer |
— | 4.60K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HLS Therapeutics Inc. |
Issuer | 500 | Redemption, retraction, cancelation, repurchase |
Hanna, John Gordon |
Director of Issuer | 12.00K | Acquisition or disposition in the public market |
Millian (Craig Stuart) |
Director of Issuer | 16.50K | Acquisition or disposition in the public market |
Fundamentals
Market cap$116.01M
Enterprise value$144.18M
Revenue (TTM)$56.24M
Gross profit$39.41M
EBITDA$17.01M
Net income$-8.57M
EPS (TTM)$-0.37
Free cash flow$20.51M
Total cash$13.73M
Total debt$41.90M
Book value / share$2.44
Shares outstanding30.94M
Float19.27M
Short % of float—
Dividend yield—
Beta (5Y)0.86
Valuation & profitability ratios
Trailing P/E—
Forward P/E-38.88
PEG ratio—
Price / sales—
Price / book1.54
EV / revenue2.56
EV / EBITDA8.48
Gross margin70.07%
Operating margin-7.88%
Profit margin-15.24%
Return on equity-14.07%
Return on assets-2.03%
Debt / equity75.86
Current ratio1.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $55.50M | $56.62M | $63.07M | $61.47M | -2.0% |
| Operating revenue | $55.50M | $56.62M | $63.07M | $61.47M | -2.0% |
| Cost of revenue | $10.08M | $9.00M | $7.62M | $4.98M | +12.1% |
| Gross profit | $45.42M | $47.62M | $55.45M | $56.49M | -4.6% |
| Selling, general & admin | $22.00M | $26.93M | $28.29M | $29.85M | -18.3% |
| Total operating expense | $49.52M | $55.31M | $65.80M | $69.98M | -10.5% |
| Operating income | -$4.11M | -$7.69M | -$10.35M | -$13.50M | +46.6% |
| Net interest income | -$6.99M | -$9.76M | -$8.40M | -$7.26M | +28.5% |
| Pre-tax income | -$12.88M | -$15.58M | -$27.80M | -$23.72M | +17.4% |
| Tax provision | -$445.00K | $4.07M | -$272.00K | -$124.00K | -110.9% |
| Net income | -$12.43M | -$19.66M | -$27.53M | -$23.60M | +36.8% |
| Net income to common | -$12.43M | -$19.66M | -$27.53M | -$23.60M | +36.8% |
| Basic EPS | -0.62 | -0.62 | -0.85 | -0.73 | 0.0% |
| Diluted EPS | -0.62 | -0.62 | -0.85 | -0.73 | 0.0% |
| EBIT | -$5.78M | -$5.50M | -$19.05M | -$16.41M | -5.1% |
| EBITDA | $16.04M | $17.22M | $12.88M | $18.00M | -6.9% |
| Basic shares | 31.70M | 31.84M | 32.26M | 32.43M | -0.4% |
| Diluted shares | 31.70M | 31.84M | 32.26M | 32.43M | -0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.72M | $17.46M | $21.95M | $20.72M | -32.8% |
| Cash & short-term investments | $11.72M | $17.46M | $21.95M | $20.72M | -32.8% |
| Accounts receivable | $7.05M | $6.72M | $9.64M | $8.90M | +4.9% |
| Inventory | $8.14M | $9.06M | $9.53M | $8.90M | -10.1% |
| Total current assets | $29.09M | $35.40M | $44.09M | $44.37M | -17.8% |
| Property, plant & equipment | $1.34M | $997.00K | $965.00K | $1.13M | +34.2% |
| Goodwill & intangibles | $105.63M | $122.12M | $162.34M | $195.02M | -13.5% |
| Total assets | $137.53M | $159.90M | $209.06M | $241.65M | -14.0% |
| Total current liabilities | $26.12M | $22.55M | $26.69M | $31.19M | +15.9% |
| Current debt | $4.33M | $4.83M | $4.69M | $13.06M | -10.4% |
| Long-term debt | $44.45M | $60.74M | $82.05M | $83.28M | -26.8% |
| Total debt | $49.82M | $66.45M | $87.62M | $97.34M | -25.0% |
| Total liabilities | $75.86M | $88.56M | $111.36M | $116.33M | -14.3% |
| Retained earnings | -$204.15M | -$194.18M | -$175.46M | -$148.45M | -5.1% |
| Shareholder equity | $61.67M | $71.34M | $97.70M | $125.32M | -13.6% |
| Working capital | $2.97M | $12.86M | $17.41M | $13.18M | -76.9% |
| Net tangible assets | -$43.96M | -$50.78M | -$64.65M | -$69.70M | +13.4% |
| Shares issued | 31.27M | 31.79M | 31.98M | 32.36M | -1.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$12.43M | -$19.66M | -$27.53M | -$23.60M | — | +36.8% |
| Depreciation & amortisation | $21.82M | $22.72M | $31.94M | $34.40M | — | -4.0% |
| Stock-based compensation | $1.91M | $1.62M | -$538.00K | $2.92M | — | +18.2% |
| Change in working capital | $4.73M | $1.14M | $5.04M | $1.55M | — | +314.9% |
| Operating cash flow | $17.13M | $8.00M | $15.79M | $16.94M | — | +114.0% |
| Capital expenditure | -$1.70M | -$15.00K | -$189.00K | -$10.15M | — | -11,253.3% |
| Investing cash flow | -$1.70M | $11.73M | -$189.00K | -$10.15M | — | -114.5% |
| Share buybacks | -$1.80M | -$600.00K | -$1.55M | -$998.00K | — | -199.8% |
| Dividends paid | — | $0 | -$2.40M | -$4.96M | -$5.12M | — |
| Financing cash flow | -$21.56M | -$23.36M | -$14.64M | -$6.86M | — | +7.7% |
| Free cash flow | $15.43M | $7.99M | $15.60M | $6.79M | — | +93.1% |
| End cash position | $11.72M | $17.46M | $21.95M | $20.72M | — | -32.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $12.86M | $15.20M | $13.51M | $14.17M | $12.62M | -15.3% |
| Operating revenue | $12.86M | $15.20M | $13.51M | $14.17M | $12.62M | -15.3% |
| Cost of revenue | $2.68M | $2.64M | $2.54M | $2.50M | $2.40M | +1.4% |
| Gross profit | $10.18M | $12.55M | $10.97M | $11.67M | $10.22M | -18.9% |
| Selling, general & admin | $5.35M | $5.22M | $5.57M | $5.59M | $5.62M | +2.6% |
| Total operating expense | $12.40M | $12.31M | $12.35M | $12.44M | $12.42M | +0.7% |
| Operating income | -$2.21M | $237.00K | -$1.37M | -$778.00K | -$2.19M | -1,034.6% |
| Net interest income | -$789.00K | -$879.00K | -$2.42M | -$1.70M | -$1.99M | +10.2% |
| Pre-tax income | -$2.29M | -$1.98M | -$3.94M | -$2.50M | -$4.46M | -15.8% |
| Tax provision | $2.00K | -$647.00K | -$17.00K | $242.00K | -$23.00K | +100.3% |
| Net income | -$2.30M | -$1.33M | -$3.92M | -$2.74M | -$4.44M | -72.1% |
| Net income to common | -$2.30M | -$1.33M | -$3.92M | -$2.74M | -$4.44M | -72.1% |
| Basic EPS | -0.07 | -0.04 | -0.12 | -0.09 | -0.14 | -75.0% |
| Diluted EPS | -0.07 | -0.04 | -0.12 | -0.09 | -0.14 | -75.0% |
| EBIT | -$1.49M | -$1.08M | -$1.49M | -$766.00K | -$2.44M | -37.7% |
| EBITDA | $4.04M | $4.38M | $4.02M | $4.72M | $2.92M | -7.7% |
| Basic shares | 31.27M | 33.38M | 31.40M | 30.46M | 31.79M | -6.3% |
| Diluted shares | 31.27M | 33.38M | 31.40M | 30.46M | 31.79M | -6.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.33M | $11.72M | $10.78M | $12.15M | $17.73M | +5.1% |
| Cash & short-term investments | $12.33M | $11.72M | $10.78M | $12.15M | $17.73M | +5.1% |
| Accounts receivable | $7.24M | $7.05M | $7.72M | $8.47M | $6.98M | +2.6% |
| Inventory | $7.36M | $8.14M | $7.11M | $6.82M | $7.48M | -9.5% |
| Total current assets | $28.95M | $29.09M | $27.49M | $30.04M | $34.07M | -0.5% |
| Property, plant & equipment | $1.17M | $1.34M | $1.27M | $1.05M | $972.00K | -12.3% |
| Goodwill & intangibles | $99.63M | $105.63M | $109.67M | $116.05M | $117.18M | -5.7% |
| Total assets | $131.09M | $137.53M | $140.23M | $149.07M | $153.95M | -4.7% |
| Total current liabilities | $28.82M | $26.12M | $23.46M | $27.59M | $23.84M | +10.3% |
| Current debt | $4.25M | $4.33M | $4.26M | $5.75M | $5.27M | -1.7% |
| Long-term debt | $38.79M | $44.45M | $48.83M | $48.97M | $57.63M | -12.7% |
| Total debt | $43.93M | $49.82M | $54.09M | $55.57M | $63.74M | -11.8% |
| Total liabilities | $72.52M | $75.86M | $78.49M | $82.51M | $87.15M | -4.4% |
| Retained earnings | -$206.45M | -$204.15M | -$202.82M | -$199.83M | -$198.33M | -1.1% |
| Shareholder equity | $58.57M | $61.67M | $61.74M | $66.56M | $66.80M | -5.0% |
| Working capital | $126.00K | $2.97M | $4.04M | $2.45M | $10.23M | -95.8% |
| Net tangible assets | -$41.06M | -$43.96M | -$47.94M | -$49.49M | -$50.38M | +6.6% |
| Shares issued | 31.27M | 31.27M | 31.28M | 31.48M | 31.74M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.30M | -$1.33M | -$3.92M | -$2.74M | -$4.44M | — | -72.1% |
| Depreciation & amortisation | $5.54M | $5.46M | $5.51M | $5.48M | $5.36M | — | +1.3% |
| Stock-based compensation | $142.00K | $11.00K | $785.00K | $465.00K | $651.00K | — | +1,190.9% |
| Change in working capital | $3.74M | $2.24M | -$739.00K | $1.28M | $1.95M | — | +67.1% |
| Operating cash flow | $6.37M | $6.51M | $2.48M | $4.60M | $3.54M | — | -2.2% |
| Capital expenditure | -$383.00K | -$316.00K | -$279.00K | -$1.09M | -$21.00K | — | -21.2% |
| Investing cash flow | -$383.00K | -$316.00K | -$279.00K | -$1.09M | -$21.00K | — | -21.2% |
| Share buybacks | $0 | -$7.00K | -$783.00K | -$833.00K | -$176.00K | — | +100.0% |
| Dividends paid | — | — | — | — | — | $0 | — |
| Financing cash flow | -$5.26M | -$5.37M | -$3.44M | -$9.46M | -$3.28M | — | +2.0% |
| Free cash flow | $5.98M | $6.19M | $2.20M | $3.52M | $3.52M | — | -3.3% |
| End cash position | $12.33M | $11.72M | $10.78M | $12.15M | $17.73M | — | +5.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.03 | +62.5% |
| Dec 2025 | -0.03 | -0.04 | -33.3% |
| Sep 2025 | -0.07 | -0.12 | -71.4% |
| Jun 2025 | -0.09 | -0.09 | -5.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.08 | 1 | $14.18M | +0.0% |
| Next quarter | -0.04 | 2 | $16.15M | +6.3% |
| Current year | -0.21 | 3 | $58.44M | +5.3% |
| Next year | -0.07 | 2 | $65.03M | +11.3% |
Analyst targets & ownership
Mean target$7.28
High target$11.87
Low target$4.39
Implied upside94.02%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders0.54%
Held by institutions44.45%
Institutions holding9
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.89
-3.50% from price
SMA 20
4.01
-6.59% from price
SMA 50
4.17
-10.07% from price
SMA 100
4.36
-14.07% from price
SMA 200
4.53
-17.25% from price
EMA 12
3.92
-4.38% from price
EMA 26
4.02
-6.79% from price
EMA 50
4.14
-9.48% from price
RSI (14)
33.5
Neutral
MACD (12,26,9)
-0.10
Hist -0.01
ATR (14)
0.20
5.32% of price
Realised vol 30D
29.2%
Annualised
Bollinger upper
4.31
20, 2σ
Bollinger lower
3.72
20, 2σ
50 / 200 cross
Death
4.17 vs 4.53
Trend bias
Below 200
-17.25%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.07
Less volatile than market
Correlation to SPY
-0.03
Largely independent
Realised vol 30D
29.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-34.4%
Peak to trough
Max drawdown 5Y
-85.2%
Peak to trough
ATR 14
0.20
5.32% of price
Beta (reported)
0.86
5Y monthly, from filing
Short interest
Shares short
9.72K
Prior 1.15K
Change vs prior
+745.7%
Shorts adding
% of float
—
—
% of shares out
0.04%
Against total outstanding
Days to cover
0.2
Liquid
Float
19.27M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 18, 24 | Raymond James | MAINTAINED | Market Perform | Market Perform |
| Aug 6, 21 | Raymond James | DOWNGRADE | Outperform | Market Perform |
Headlines
Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?
Motley Fool · 8m ago
Sell U.S. dollar versus these currencies, BCA says
Investing.com · 12m ago
Democrat Angie Nixon stunned politicos in Florida's primary. Can she win again?
Orlando Sentinel · 12m ago
Synaptics' CFO Disposed of Stock as an 88%-12% OnSemi Ownership Split Takes Shape. Here's What to Know
Motley Fool · 13m ago
The Ultimate Growth Stock to Buy With $1,000 Right Now -- It's Been My Best Stock Performer by Far
Motley Fool · 27m ago
The S&P 500 Just Did Something Seen Only 1 Other Time Since 1871 — and It's Not Good News for Wall Street
Motley Fool · 28m ago
AWS Was Lagging Microsoft Azure and Google Cloud in Growth—Is Amazon Finally Catching Up?
Insider Monkey · 31m ago
Iran warns neighbours against joining U.S. sanctions as Hormuz stays closed
Investing.com · 33m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.